Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I HIPEC with Paclitaxel, Mitomycin, and Cisplatin in Gastric Cancer
NCT03330028Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2017
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose and Dose Limiting Toxicity. Started Oct 2017; status: completed.
02
Drugs
paclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03330028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03330028.